% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Adolph:166506,
author = {J. E. Adolph and G. Fleischhack and R. Mikasch and J.
Zeller and M. Warmuth-Metz and B. Bison and M. Mynarek and
S. Rutkowski and U. Schüller and K. von Hoff and D. Obrecht
and T. Pietsch and S. M. Pfister$^*$ and K. W. Pajtler$^*$
and O. Witt$^*$ and H. Witt$^*$ and R.-D. Kortmann and B.
Timmermann and J. Krauß and M. C. Frühwald and A. Faldum
and R. Kwiecien and U. Bode and S. Tippelt},
collaboration = {G. G. HIT-Network},
title = {{L}ocal and {S}ystemic {T}herapy of {R}ecurrent
{E}pendymoma in {C}hildren and {A}dolescents: {S}hort- and
{L}ong-term {R}esults of the {E}-{HIT}-{REZ} 2005 {S}tudy.},
journal = {Neuro-Oncology},
volume = {23},
number = {6},
issn = {1523-5866},
address = {Oxford},
publisher = {Oxford Univ. Press},
reportid = {DKFZ-2020-02949},
pages = {1012-1023},
year = {2021},
note = {2021 Jun 1;23(6):1012-1023},
abstract = {Survival in recurrent ependymomas in children and
adolescents mainly depends on the extent of resection.
Studies on repeated radiotherapy and chemotherapy at relapse
have shown conflicting results.Using data from the German
multi-center E-HIT-REZ-2005 study, we examined the role of
local therapy and the efficacy of chemotherapy with
blockwise temozolomide (TMZ) in children and adolescents
with recurrent ependymomas.53 patients with a median age of
6.9 years (1.25-25.4) at 1 st recurrence and a median
follow-up time of 36 months (2-115) were recruited. Gross
and near total resection (GTR/NTR) were achieved in 34
$(64.2\%)$ patients and associated with a markedly improved
5-year overall survival (OS) of $48.7\%$ vs. $5.3\%$ in less
than GTR/NTR. Radiotherapy showed no improvement in OS
following complete resection (OS: 70 (CI: 19.9-120.1) vs. 95
(CI: 20.7-169.4) months), but an advantage was found in less
than GTR/NTR (OS: 22 (CI: 12.7-31.3) vs. 7 (CI: 0-15.8)
months). Following application of TMZ, disease progression
was observed in most evaluable cases (18/21). Subsequent
change to oral etoposide and trofosfamide showed no improved
response. PF-A EPN were most abundant in relapses (n = 27).
RELA-positive EPN (n=5) had a 5-year-OS of $0\%.The$ extent
of resection is the most important predictor of survival at
relapse. Focal re-irradiation is a useful approach if
complete resection cannot be achieved, but no additional
benefit was seen after GTR/NTR. Longer-term disease
stabilization (>6 months) mediated by TMZ occurred in a
small number of cases $(14.3\%).$},
keywords = {chemotherapy (Other) / ependymoma (Other) / radiotherapy
(Other) / relapse (Other) / tumor resection (Other)},
cin = {B062 / B310},
ddc = {610},
cid = {I:(DE-He78)B062-20160331 / I:(DE-He78)B310-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:33331885},
doi = {10.1093/neuonc/noaa276},
url = {https://inrepo02.dkfz.de/record/166506},
}